← Back to all signals
RESEARCH PAPER ANALYSIS

Resting-State EEG Features of Cognitive Fluctuations Across the Lewy Body Disease Spectrum.

Resting-state EEG measures—lower dominant frequency, reduced alpha prevalence (DFP-alpha), and lower individual alpha peak frequency—distinguish Lewy body disease patients with cognitive fluctuations from those without, with anterior DFP-alpha yielding an AUC ≈0.85.

PMID41960336
JournalResearch square
Publication Date2026-03-31
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Resting-state EEG measures—lower dominant frequency, reduced alpha prevalence (DFP-alpha), and lower individual alpha peak frequency—distinguish Lewy body disease patients with cognitive fluctuations from those without, with anterior DFP-alpha yielding an AUC ≈0.85.

WHY IT MATTERS

Research significance

This identifies a noninvasive, readily obtainable biomarker for detecting and stratifying cognitive fluctuations in Lewy body disease, aiding diagnosis and clinical trial enrichment, though it offers limited direct mechanistic or therapeutic targets.

ABSTRACT

Source abstract

BACKGROUND: Cognitive fluctuations (CF) are a core feature of Lewy body dementia (LBD) that negatively impact quality of life. Despite their prevalence and negative impact, CF are challenging to identify clinically. The goal of this study was to identify easily obtainable EEG features associated with CF across the spectrum of Lewy body disease (LB). METHODS: We conducted a cross-sectional study of 53 patients prospectively enrolled through the outpatient clinics of the Department of Neurology at Virginia Commonwealth University. Based on the Clinician Assessment of Fluctuations, participants were categorized as LB disease without CF (LB-CF) or LB disease with CF (LB + CF). All participants underwent a resting-state EEG recording with eyes closed for at least 3 minutes. EEG data were preprocessed and the following features were extracted: dominant frequency (DF), dominant frequency variability (DFV), dominant frequency prevalence (DFP), and individual alpha peak frequency (IAF). We applied Kruskal-Wallis tests and logistic regression models to evaluate differences in EEG features between study groups. RESULTS: We analyzed EEG features for 29 LB + CF and 24 LB-CF participants. Compared to the LB-CF group, the LB + CF group had significantly lower DF, DFP-alpha, and IAF in all derivations (all p < 0.05). In logistic regression analysis adjusting for age, sex, and MoCA score, these EEG features remained significant predictors of group (LB + CF vs. LB-CF, all q < 0.05). The elastic-net logistic regression model identified five predictors (anterior DFP-alpha, anterior DFP-theta, anterior DF, temporal DF, temporal IAF, and posterior DFP-pre-alpha) achieving an AUC of 0.86, whereas anterior DFP-alpha alone achieved an AUC of 0.85. CONCLUSION: Among patients with LB disease, resting-state EEG features were associated with CF and were significant predictors of CF even after adjustment for age, sex, and MoCA. The development of an EEGbased biomarker of CF using this set of features could improve diagnosis of Lewy body dementia.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic